Clinical trial
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of LXI-15028 in the Treatment of Non-erosive Reflux Disease in Chinese Patients for 4 Weeks
NCT03591653 is registered in ClinicalTrials.gov with Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center, Randomized, Double-blind, Parallel-group, Placebo Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of LXI-15028 in the Treatment of Non-erosive Reflux Disease in Chinese Patients for 4 Weeks
- Lead sponsor
- Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 29, 2018
- Completion date
- November 26, 2019
- Enrollment
- 291 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.